Generate Biomedicines, Inc. Common Stock (GENB) Stock Price
GENBStock
$12.09
Market Cap$1.55B
P/E—
PEG Ratio—
Div yield—
Beta0.48
GENB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-16.11%
Price vs S&P 500 (4W)-29.11%
VGM Score36.06
GENB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.49 | -$0.52 | -5.58%(-$0.03) | |
| Q1 2026 | -$0.51 | -$1.07 | -111.18%(-$0.56) |
GENB Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.09
4.17
4.17
4.17
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. Common Stock | — | F | C | — | — | — | — | $12.09 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to design novel protein therapeutics. Its proprietary Generate Platform enables rapid drug discovery and development across multiple therapeutic modalities. The company's pipeline includes three clinical candidates: GB-0895, GB-4362, and GB-5267.